CSL Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
pharmaceutical manufacturers in Australasia:
Mayne Pharma Group Limited
sales of 457.77 million Australian Dollars [US$351.86 million]
of which 55%
was Generic Products),
(107.22 million Australian Dollars [US$82.41 million]
AFT Pharmaceuticals Ltd
based in NEW ZEALAND
(105.60 million New Zealand Dollars [US$75.21 million]
of which 58%
During the second
quarter of 2021, sales at CSL Limited totalled
an increase of 7.4%
from the A$7.33 billion in sales at the company during the second quarter of 2020.
CSL Limited reported sales of A$13.65 billion (US$10.49 billion)
June of 2020.
increase of 14.3%
versus 2019, when the company's sales were A$11.95 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2015, sales have increased a total of 101%).
Sales of Seqirus saw an increase
18.9% in 2020, from
A$1.42 billion to A$1.69 billion.